Education
About Us
Working with TipRanks
Follow Us
Zoetis (ZTS)
:ZTS
ZTS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$139.70 - $200.33
Previous CloseN/A
Volume625.10K
Average Volume (3M)2.78M
Market Cap
$66.56B
Enterprise Value$78.31B
Total Cash (Recent Filing)$113.00M
Total Debt (Recent Filing)$579.00M
Price to Earnings (P/E)27.3
Beta0.66
Next Earnings
May 06, 2025EPS Estimate
1.42Next Dividend Ex-Date
Apr 21, 2025Dividend Yield1.2%
Share Statistics
EPS (TTM)5.46
Shares Outstanding446,060,900
10 Day Avg. Volume3,391,045
30 Day Avg. Volume2,780,848
Financial Highlights & Ratios
PEG Ratio3.55
Price to Book (P/B)N/A
Price to Sales (P/S)7.89
Price to Cash Flow (P/CF)20.20
P/FCF Ratio19.30
Enterprise Value/Market Cap1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.98
Enterprise Value/Ebitda19.97
Forecast
1Y Price Target
$205.57Price Target Upside40.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Zoetis News
PremiumCompany Announcements
Zoetis Reports Robust Growth Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Analyst ConfidenceAnalyst reiterates a BUY rating for Zoetis, highlighting confidence in the company's growth potential.
Market LeadershipZoetis is viewed as a market leader in an industry with durable secular growth drivers, reinforcing the positive outlook.
Product GrowthZoetis' top 5, top 10, and top 20 products showed over 20% year-over-year growth, indicating success beyond just a few offerings.
Bears Say
Divestiture ImpactThe divestiture of ZTS' medicated feed additives and water business is expected to lower revenue and adjusted EPS estimates for 2025 and 2026.
Foreign Exchange ImpactForeign exchange headwinds are anticipated to negatively impact Zoetis's revenue and net income in 2025.
Revenue DeclineRevenue from all other product sales was down roughly 4% year-over-year, outside of the top 10 products.
---
Ownership Overview
0.07% Insiders
20.58% Mutual Funds
1.09% Other Institutional Investors
56.17% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZTS FAQ
What was Zoetis’s price range in the past 12 months?
Zoetis lowest stock price was $139.70 and its highest was $200.33 in the past 12 months.
What is Zoetis’s market cap?
Zoetis’s market cap is $66.56B.
When is Zoetis’s upcoming earnings report date?
Zoetis’s upcoming earnings report date is May 06, 2025 which is in 19 days.
How were Zoetis’s earnings last quarter?
Zoetis released its earnings results on Feb 13, 2025. The company reported $1.4 earnings per share for the quarter, beating the consensus estimate of $1.362 by $0.038.
Is Zoetis overvalued?
According to Wall Street analysts Zoetis’s price is currently Undervalued.
Does Zoetis pay dividends?
Zoetis pays a Quarterly dividend of $1.796 which represents an annual dividend yield of 1.2%. See more information on Zoetis dividends here
What is Zoetis’s EPS estimate?
Zoetis’s EPS estimate is 1.42.
How many shares outstanding does Zoetis have?
Zoetis has 446,060,900 shares outstanding.
What happened to Zoetis’s price movement after its last earnings report?
Zoetis reported an EPS of $1.4 in its last earnings report, beating expectations of $1.362. Following the earnings report the stock price went down -5.147%.
Which hedge fund is a major shareholder of Zoetis?
Currently, no hedge funds are holding shares in ZTS
---
Zoetis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$205.57 (40.07% Upside)
$205.57 (40.07% Upside)
Blogger Sentiment
Bullish
ZTS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 212.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $260.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.06%
12-Months-Change
Fundamentals
Return on Equity
50.91%
Trailing 12-Months
Asset Growth
-0.34%
Trailing 12-Months
Company Description
Zoetis
Zoetis Inc. is a leading global animal health company dedicated to supporting veterinarians and livestock producers in improving the health and well-being of animals. Operating in the animal pharmaceuticals and diagnostics sectors, Zoetis provides a comprehensive portfolio of medicines, vaccines, diagnostic products, and services for both companion animals and livestock. The company's products are designed to prevent and treat diseases, enhance animal productivity, and ensure food safety.
---
ZTS Company Deck
---
ZTS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Zoetis reported strong financial performance with significant growth in key product segments, particularly in companion animals and dermatology. Despite facing headwinds from foreign exchange and increased competition, the company remains confident in its ability to sustain above-market growth driven by innovation and strategic investments.Read More>---
ZTS Revenue Breakdown
67.83% Companion animal
31.31% Livestock
0.86% Contract manufacturing & human health
---
ZTS Stock 12 Month Forecast
Average Price Target
$205.57
▲(40.07% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Phibro Animal Health
―
HUTCHMED
―
Elanco Animal Health
―
Best Analysts Covering ZTS
1 Year
1 Year Success Rate
16/23 ratings generated profit
1 Year Average Return
+14.38%
reiterated a buy rating 2 months ago
Copying Erin Wright's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +14.38% per trade.
---